25th ICON MEET- 16th-18th September, 2011 at Hotel Center Point, Nagpur.

25th ICON MEET- 16th-18th September, 2011 at Hotel Center Point, Nagpur.

 

About The Event

About:

 

To aim for better prevention and management of human cancers in this country.
To foster and encourage cooperative clinical research in oncology at a national level.
To participate in all phases of clinical research in oncology while upholding respect for individual patients.
To generate data that is of high quality, ethical, complies with good clinical practices and which is acceptable to regulatory and statutory bodies /authorities.
To disseminate such knowledge at local, regional, national and international levels.

To promote the development of Oncology as a subspecialty in India.

List of Active ICON Protocols

1.    A Phase II study of Gemcitabine as 4 hour infusion with carboplatin in inoperable stage III and IV NSCLC (Protocol No: ICON/ LUNG/ 0105) Status: 

2.    Comprehensive Management for patients with Chronic Myeloid Leukemia (Protocol TMC/CML/MO-0401; Version Date 20 April 2004) – a phase II feasibility and tolerability study. Status: Ongoing 

3.    Combination Chemotherapy for MM (Protocol No: ICON/Hematol-MM/0306) Status: Ongoing 

4.    A phase II b RCT of Neo adjuvant chemotherapy comparing Paclitaxel, Ifosfamide and Cisplatin with Paclitaxel, Cisplatin and 5-FU in patients with locally advanced head & neck cancer. (Protocol No: ICON/H&N/0601) Status: Ongoing 

5.    An open label, multicentre phase I/II dose escalating study of Pablocan (NPB001-05) in patients of chronic myeloid leukemia who have demonstrated resistance / intolerance to the local prevailing standard of care.(Protocol No: ICON/CML/0701) Status: Ongoing 

6.    An Observational Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients with Platinum Sensitive Epithelial Relapsed Ovarian Cancer. (Protocol No: ICON/Ovary/0703) Status: Ongoing 

7.    A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine)  (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) Who have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy (Protocol No. CGX-635-CML-203) Status: Ongoing 

8.    A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine) (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation (Protocol No. CGX-635-CML-202) Status: Ongoing 

9.   Neo-Adjuvant Docetaxel + Platinum for Locally Advanced Breast Cancer: A  single arm observational study (ICON/LABC/0108)Status: proposed


Invite friends

Contact Us

Page Views : 1645

Venue Map